Edition:
United Kingdom

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

7.32USD
22 Jun 2018
Change (% chg)

$0.08 (+1.10%)
Prev Close
$7.24
Open
$7.25
Day's High
$7.39
Day's Low
$7.16
Volume
566,194
Avg. Vol
377,103
52-wk High
$11.26
52-wk Low
$4.32

Chart for

About

Depomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $369.12
Shares Outstanding(Mil.): 62.99
Dividend: --
Yield (%): --

Financials

  DEPO.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.79 -- --
ROI: -12.06 14.84 14.38
ROE: -43.53 16.34 16.08

BRIEF-Starboard Value Cuts Stake In Depomed Inc To 4.3 Pct

* STARBOARD VALUE LP CUTS STAKE IN DEPOMED INC TO 4.3 PERCENT AS OF MAY 18 FROM PREVIOUS STAKE OF 6.1 PERCENT AS OF MAY 10 - SEC FILING Source text: (https://bit.ly/2J3k2sc) Further company coverage:

22 May 2018

BRIEF-Depomed Q1 Earnings Per Share $0.48

* Q1 EARNINGS PER SHARE VIEW $0.17 -- THOMSON REUTERS I/B/E/S

10 May 2018

BRIEF-Depomed Appoints Stan Bukofzer As Chief Medical And Scientific Officer

* DEPOMED ANNOUNCES THE APPOINTMENT OF STAN BUKOFZER, M.D. AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL AND SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

02 Apr 2018

BRIEF-Depomed Inc Files For Mixed Shelf Of Up To $300 Million‍​

* DEPOMED INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING ‍​ Source text (http://bit.ly/2oD3GLe) Further company coverage:

02 Mar 2018

BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52

* ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

27 Feb 2018

Earnings vs. Estimates